Qian Cao
Director/Board Member chez NINGBO MENOVO PHARMACEUTICAL CO., LTD.
Fortune : 508 146 $ au 31/03/2024
Profil
Qian Cao has worked as a Director at Zhejiang Liaoyuan Pharmaceutical Co., Ltd.
since 2015 and at Ningbo Menovo Pharmaceutical Co., Ltd.
since 2018.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
19/03/2023 | 192 103 ( 0,09% ) | 372 647 $ | 31/03/2024 | |
19/03/2023 | 69 851 ( 3,11% ) | 135 499 $ | 31/03/2024 |
Postes actifs de Qian Cao
Sociétés | Poste | Début |
---|---|---|
NINGBO MENOVO PHARMACEUTICAL CO., LTD. | Director/Board Member | 20/06/2018 |
Zhejiang Liaoyuan Pharmaceutical Co., Ltd.
Zhejiang Liaoyuan Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Zhejiang Liaoyuan Pharmaceutical Co., Ltd. engages in the manufacturing of APIs and intermediates for anticoagulants, antidepressants, and cardiovascular drugs. Its products include Clopidogrel, Ticlopidine Hydrochloride, Mirtazapine, 2-thiophene ethanol, 2-thiophene ethylamine, and other related pharmaceutical products. The company was founded on March 26, 1994 and is headquartered in Linhai, China. | Director/Board Member | 25/04/2015 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
NINGBO MENOVO PHARMACEUTICAL CO., LTD. | Health Technology |
Entreprise privées | 1 |
---|---|
Zhejiang Liaoyuan Pharmaceutical Co., Ltd.
Zhejiang Liaoyuan Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Zhejiang Liaoyuan Pharmaceutical Co., Ltd. engages in the manufacturing of APIs and intermediates for anticoagulants, antidepressants, and cardiovascular drugs. Its products include Clopidogrel, Ticlopidine Hydrochloride, Mirtazapine, 2-thiophene ethanol, 2-thiophene ethylamine, and other related pharmaceutical products. The company was founded on March 26, 1994 and is headquartered in Linhai, China. | Health Technology |